文献速递治疗药物监测与药物基因组学抗栓抗凝管理特殊人群用药

衰老对经皮冠状动脉介入治疗后基因型指导P2Y12抑制剂选择临床结局的影响

Effects of aging on clinical outcomes in patients receiving genotype-guided P2Y12 inhibitor selection after percutaneous coronary intervention.
PubMed 文献 · Pharmacotherapy · 2021-07-21

单中心回顾性队列研究纳入1469例PCI后行CYP2C19基因检测患者,比较≥70岁与<70岁患者中基因型指导P2Y12抑制剂选择的临床有效性。结果显示,在氯吡格雷治疗患者中,无功能等位基因携带者MACCE风险显著高于非携带者,且此关联在老年和年轻组中均存在。研究提示CYP2C19基因型指导抗血小板治疗在老年和年轻患者中均有重要临床获益。

要点

  • ≥70岁患者中,氯吡格雷治疗的无功能等位基因携带者MACCE风险显著高于非携带者(19.2% vs 12.7%;调整HR 2.32)。
  • <70岁患者中,氯吡格雷治疗的无功能等位基因携带者MACCE风险亦显著高于非携带者(17.4% vs 10.4%;调整HR 2.01)。
  • 无功能等位基因非携带者中,氯吡格雷与普拉格雷/替格瑞洛的MACCE风险在老年和年轻组中均相似。

核心结论

  • 本研究提示CYP2C19基因型指导的PCI后抗血小板治疗在年轻和老年患者中均有重要临床获益。

研究设计与样本

  • 单中心、回顾性队列研究,纳入1469例接受PCI并完成CYP2C19基因检测的患者。
  • 比较≥70岁组(402例,27.4%)与<70岁组(1067例,72.6%)的临床结局。
  • 主要终点为PCI后12个月内主要不良心脑血管事件(MACCE),采用比例风险回归分析。

主要发现

  • 在CYP2C19无功能等位基因携带者中,≥70岁组使用替代P2Y12抑制剂(普拉格雷或替格瑞洛)的比例低于<70岁组(55% vs 67%;p=0.02)。
  • 在无无功能等位基因患者中,≥70岁组使用替代P2Y12抑制剂的比例亦低于<70岁组(10% vs 35%;p<0.001)。
  • 氯吡格雷治疗的无功能等位基因携带者较非携带者MACCE风险在≥70岁组显著升高(19.2% vs 12.7%;调整HR 2.32;95%CI 1.07-5.05;p=0.03)。
  • 氯吡格雷治疗的无功能等位基因携带者较非携带者MACCE风险在<70岁组亦显著升高(17.4% vs 10.4%;调整HR 2.01;95%CI 1.17-3.46;p=0.01)。
  • 无无功能等位基因患者中,氯吡格雷与普拉格雷/替格瑞洛的MACCE风险在≥70岁组(调整HR 0.99;95%CI 0.44-2.21;p=0.98)和<70岁组(调整HR 1.12;95%CI 0.72-1.74;p=0.61)均相似。

临床怎么用

  • PCI后患者应行CYP2C19基因检测,以指导P2Y12抑制剂选择。
  • CYP2C19无功能等位基因携带者使用氯吡格雷时MACCE风险较高,应考虑替代P2Y12抑制剂(普拉格雷或替格瑞洛)。
  • 无功能等位基因非携带者使用氯吡格雷与替代P2Y12抑制剂的MACCE风险相似。

局限性

  • 单中心回顾性队列研究,结果可能受选择偏倚和混杂因素影响。
  • 研究未报告盲法或随机化信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To compare the clinical effectiveness of genotype-guided P2Y12 inhibitor selection following PCI in older patients (≥70 years) and younger patients (<70 years). DESIGN AND SETTING: Single-center, retrospective, cohort study. Risk of major adverse cardiovascular or cerebrovascular events (MACCE), defined as stent thrombosis, ischemic stroke, transient ischemic attack, non-fatal acute coronary syndrome, or cardiovascular death during 12 months after PCI, was compared across genotype and antiplatelet therapy groups by proportional hazards regression in patients ≥70 years and <70 years. PATIENTS: 1,469 patients who underwent PCI and had CYP2C19 genotype testing at a single academic medical center. MEASUREMENTS AND MAIN RESULTS: The study population was comprised of 402 (27.4%) ≥70 years (older group) and 1067 (72.6%) <70 years (younger group). Alternative P2Y12 inhibitors (prasugrel or ticagrelor) were used less often in the older group than the younger group in patients with a CYP2C19 no function allele (55% vs. 67%; p = 0.02) and in patients without a no function allele (10% vs. 35%, p < 0.001). For patients treated with clopidogrel, MACCE was significantly higher in no function allele carriers compared to those without a no function allele in the older group (19.2% vs. 12.7%; adjusted HR 2.32; 95% CI 1.07-5.05; p = 0.03) and the younger group (17.4% vs. 10.4%; adjusted HR 2.01; 95% CI 1.17-3.46; p = 0.01). In patients without a no function allele, MACCE risk was similar with clopidogrel compared to prasugrel or ticagrelor in the older group (adjusted HR 0.99; 95% CI 0.44-2.21; p = 0.98) and the younger group (adjusted HR 1.12; 95% CI 0.72-1.74; p = 0.61). CONCLUSION: This study suggests important clinical benefits of CYP2C19 genotype-guided antiplatelet therapy after PCI in both younger and older patients.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Wood B, Lee CR, Mulrenin IR, et al. Effects of aging on clinical outcomes in patients receiving genotype-guided P2Y12 inhibitor selection after percutaneous coronary intervention. Pharmacotherapy. 2021. PMID: 34242414. doi:10.1002/phar.2611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。